Gujarat Themis Biosyn Q4 FY26: Growth Holds, While Acquisitions Reset the Scale

Gujarat Themis Biosyn Limited closed Q4 FY2025-26 with steady volume-led growth and a clear shift toward bigger strategic moves. Revenue rose 17.22 percent year on year to Rs. 44.23 crores. EBITDA increased 20.71 percent to Rs. 19.36 crores, with EBITDA margin improving to 43.77 percent from 42.50 percent last year. Profit after tax came in at Rs. 10.89 crores, down 9.22 percent year on year, and EPS for the quarter was Rs. 1.00.

Management framed the quarter as the result of resilient demand and operational efficiencies. The story is not just about another strong fermentation cycle at Vapi. It is also about a company preparing for a step change through inorganic growth. During the year, Gujarat Themis Biosyn signed an asset purchase agreement to acquire a portfolio of 13 brands from Sanofi, France, and also signed a share purchase agreement to acquire MicroBioPharm Japan Co., Ltd. via a wholly owned subsidiary in Japan.

For investors, Q4 FY26 matters because it shows two realities at once. Core operations still generate high operating margins. But the cost structure is changing due to expansion, higher manpower and operating expenses, and higher depreciation and interest. At the same time, the company is laying the groundwork for a much larger global footprint in tuberculosis and anti-infective therapies and for a longer-term transition toward a fermentation-based CDMO platform.

Q4 FY26 performance: growth came through volumes, not leverage alone

Quarterly revenue has been trending up through FY26. Income from operations moved from Rs. 35.9 crores in Q1 FY26 to Rs. 44.2 crores in Q4 FY26. The trend is consistent with management commentary that sales volumes remained robust and demand was steady.

Margins were healthy in Q4, but they also show the push and pull in the cost base. EBITDA margin for Q4 FY26 was 43.77 percent, slightly higher than Q4 FY25, helped by operating leverage from higher volumes and cost rationalizations. However, EBITDA was lower sequentially versus Q3 FY26, when margin was 49.13 percent. This sequential compression is visible in the expense line too. Other costs increased to Rs. 17.52 crores in Q4 FY26 from Rs. 11.48 crores in Q3 FY26. Employee costs were lower sequentially at Rs. 3.79 crores versus Rs. 4.76 crores in Q3, but still up versus Q4 FY25.

The sharper movement came below EBITDA. Depreciation rose to Rs. 4.04 crores in Q4 FY26 from Rs. 1.23 crores in Q4 FY25. Interest expense also increased to Rs. 1.91 crores from Rs. 0.07 crores last year. As a result, profit before tax declined 10.88 percent year on year, and PAT margin fell to 24.62 percent from 31.79 percent in Q4 FY25.

A key point is that the profitability pressure is not coming from a collapse in operating performance. It is coming from a company that is investing, scaling, and preparing for integration and larger operations.

FY26: revenue growth continued, while returns fell due to capex-led balance sheet expansion

For the full year, income from operations grew 9.96 percent to Rs. 165.82 crores. EBITDA rose 9.71 percent to Rs. 75.53 crores, and the EBITDA margin was steady at 45.55 percent. But PAT declined 4.29 percent to Rs. 46.68 crores and PAT margin fell to 28.15 percent from 32.34 percent.

This is consistent with the quarter-level trend: the business still throws off strong operating margins, but depreciation and interest are now structurally higher. Depreciation increased to Rs. 12.92 crores in FY26 from Rs. 5.37 crores in FY25. Interest cost rose to Rs. 2.95 crores from Rs. 0.36 crores. Profit before tax therefore declined 5.26 percent despite the rise in revenue and EBITDA.

The balance sheet confirms the capex cycle. Total assets increased to Rs. 503.43 crores as on 31st March 2026 from Rs. 301.31 crores as on 31st March 2025. Property, plant and equipment rose sharply to Rs. 286.92 crores from Rs. 40.58 crores, while capital work in progress reduced to Rs. 121.13 crores from Rs. 184.41 crores, suggesting commissioning and capitalization of projects.

Funding also shifted. Non-current borrowings increased to Rs. 128.06 crores from Rs. 29.64 crores. Current liabilities expanded as well, with short term borrowings at Rs. 31.80 crores and trade payables at Rs. 36.65 crores. Cash and cash equivalents reduced to Rs. 3.12 crores from Rs. 11.69 crores.

The impact shows up in return ratios. RoCE dropped to 14.5 percent in FY25-26 from 23.6 percent in FY24-25. RoA fell to 9 percent from 16 percent. RoE declined to 16.2 percent from 19.6 percent. The company directly attributes this decline to capex over the last two years, which has lifted capital employed and the asset base.

In plain terms, FY26 looks like a transition year. Earnings stayed strong, but the denominator for returns expanded faster due to investment and debt-funded buildout.

Strategy: two acquisitions change the growth runway

The most important part of the presentation is strategic, not quarterly. Gujarat Themis Biosyn is moving beyond being a niche fermentation-based intermediates manufacturer into a more integrated and global platform.

Sanofi portfolio acquisition: asset-light access to regulated markets

The company signed an agreement with Sanofi, France to acquire a portfolio of 13 brands focused on tuberculosis and anti-infectives. The deal value is approximately EUR 158 million, funded via a mix of debt and equity. The portfolio generated approximately EUR 62 million in revenue in FY 2025 actuals. The brands have reach in more than 55 countries, spanning Europe, MEA, and other markets, with around 70 percent of revenue coming from the retail channel.

Structurally, the acquisition is designed as an asset purchase. It includes brands, marketing authorizations, dossiers, and inventory, without manufacturing capex or employee transfer. This matters because it shortens execution time. Gujarat Themis Biosyn gains immediate access to regulated markets without first having to replicate manufacturing or commercial teams from scratch.

The strategic logic also fits the company’s existing strengths. The presentation describes value chain integration from intermediates to API to finished dosage, leveraging fermentation capabilities and driving forward integration. Financially, the company expects the transaction to be EPS accretive with healthy gross margins, with further upside from API integration, cost optimization, and reactivation of dormant marketing authorizations across the country footprint.

MicroBioPharm Japan acquisition: scale, technology, and CDMO positioning

The second transaction is larger and more transformative. Gujarat Themis Biosyn signed a share purchase agreement to acquire 100 percent of MicroBioPharm Japan Co., Ltd. through a wholly owned SPV in Japan. The deal value is JPY 21.5 billion, approximately INR 1,300 crores, with expected close in Q2 FY2027 subject to regulatory approvals. The target’s FY26E revenue is JPY 9.5 billion, approximately INR 575 crores.

The rationale here is breadth and capability. MicroBioPharm Japan broadens the company’s API and intermediates portfolio across oncology, immunosuppressants, and peptides, adding product depth and revenue diversification. It also brings a customer base that includes long-standing relationships with top global pharma customers, with 40 percent of revenues from outside Japan across Asia, Europe, and North America.

Technology is another pillar. The presentation calls out proprietary platforms including a P450 enzyme library, plasmid DNA, ADC conjugation, and strain and process optimization technologies. These are positioned as tools to accelerate Gujarat Themis Biosyn’s move toward a fermentation CDMO model with expanded API, biologics, and precision fermentation capabilities.

For investors, the acquisition narrative is important because it reframes the company’s scale. FY26 standalone revenue was Rs. 165.82 crores. The target’s FY26E revenue, stated in INR terms, is approximately Rs. 575 crores. Integration and execution risk will matter, but the intent is clear: the company is aiming for a scaled, innovation-led end-to-end pharma platform.

Capex, R&D, and energy: building the base for the next cycle

Even before these deals, Gujarat Themis Biosyn has been investing to expand capability at home.

The presentation notes that the R&D and API units in India are up and running and development of a new fermentation block is complete. Management also disclosed that R&D spend in FY26 was approximately 9 percent of topline. This is a meaningful level of reinvestment for a company still defined by two core intermediates.

The product base remains centered on rifamycin intermediates.

Rifamycin S is used as an intermediate for manufacturing rifampicin, an antibiotic used for several bacterial infections including tuberculosis. Rifamycin O is an intermediate for rifaximin, used for conditions including traveler’s diarrhea, irritable bowel syndrome, and hepatic encephalopathy. The presentation states capacities of up to 990 KL.

Strategy slides add context on where the next set of growth levers are expected to come from: new product development, forward integration into APIs, and expanded fermentation capacity for newly developed products across domestic and export markets.

An additional lever is cost and sustainability. The company is setting up a hybrid wind-solar renewable power project in Gujarat for captive consumption. The stated capacity is around 18 MW. The goal is to reduce dependence on grid electricity, improve energy security for manufacturing, and optimize long-term power costs. The framing is both ESG and margin stability. For a fermentation-heavy operation, energy cost control can be an understated driver of long-term competitiveness.

What to watch: strong operating economics, but a changing financial profile

Gujarat Themis Biosyn is still showing the traits that made it investable in the first place: high operating margins, robust demand-led volumes, and a niche position as one of India’s few fermentation-based intermediate manufacturers. Q4 FY26 showed that even with higher expenses, EBITDA grew faster than revenue, and the company sustained a 40-plus percent EBITDA margin.

But the financial profile is evolving. Depreciation and interest have moved up as capex has been capitalized and borrowings have increased. Return ratios have come off sharply as assets expanded. This is not necessarily negative, but it changes the investor lens from a high-return, smaller base story to an execution-driven scaling story.

The two acquisitions reinforce that shift. The Sanofi portfolio deal is positioned as asset-light and immediately commercial, potentially supporting revenue and margin through established brands across 55-plus countries. The Japan acquisition is positioned as a platform move, bringing scale, new technologies, and global customer access, with closing expected in Q2 FY2027.

The quarterly theme, then, is sustained growth with strategic ambition. If the company can keep its core fermentation engine stable, integrate new products and capabilities without diluting margins, and manage debt and working capital as it scales, the next few years could look very different from the last five. FY26 may be remembered as the year Gujarat Themis Biosyn built the base and signed up for a larger stage.